Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

406 articles

Keyword: Poractant-alphaClear keyword

Journal of controlled release : official journal of the Controlled Release Society2026ResearchNon-viral Gene DeliveryDrug Delivery

1. Lung surfactants as a component of lipid nanoparticles for pulmonary mRNA delivery

Nasr Ss, Tabah Oe, Kumar S, Poore S, Duncan Ga

Pulmonary delivery of lipid nanoparticles (LNPs) remains an area of significant interest, given the broad range of genetic disorders that could be addressed through localized administration of therapeutic nucleic acids to the lung. In this study, we investigated how incorporation of the clinically used lung surfactant cocktail Poractant alfa affects the in vitro and in vivo transfection performance of mRNA-loaded LNPs.

Endosomal escape Lipid nanoparticles Poractant-alpha Pulmonary mRNA delivery

Read the article

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes, licensing and GMP supply.InvestorsDownload our capabilities deckPlatform, pipeline milestones, manufacturing and partnership models in one PDF.